Executive at Myriad Genetics (MYGN) adds 5,000 shares via ESPP plan

Rhea-AI Filing Summary

Myriad Genetics Chief Commercial Officer Brian J. Donnelly acquired 5,000 shares of common stock through the company’s Amended and Restated 2012 Employee Stock Purchase Plan. The shares were acquired at a price of $3.936 per share in a transaction exempt under Rule 16b-3(d) and Rule 16b-3(c).

After this acquisition, Donnelly directly holds 573,363 shares of Myriad Genetics common stock, indicating this is a relatively small, routine, compensation-related increase in his overall equity position rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Donnelly Brian J

Role Chief Commerical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,000	$3.936	$20K

Holdings After Transaction: Common Stock — 573,363 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 5,000 shares Acquisition price: $3.936 per share Shares owned after transaction: 573,363 shares +2 more

5 metrics

Shares acquired 5,000 shares Common Stock acquired on 2026-06-11

Acquisition price $3.936 per share Price under employee stock purchase plan

Shares owned after transaction 573,363 shares Direct holdings following acquisition

Transaction code Code A Grant, award, or other acquisition

Rule exemption Rule 16b-3(d) and Rule 16b-3(c) Plan-based transaction exemption

Key Terms

Amended and Restated 2012 Employee Stock Purchase Plan, Rule 16b-3(d), Rule 16b-3(c), Grant, award, or other acquisition

4 terms

Amended and Restated 2012 Employee Stock Purchase Plan financial

"These shares were acquired under the Issuer's Amended and Restated 2012 Employee Stock Purchase Plan"

Rule 16b-3(d) regulatory

"transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)"

Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.

Rule 16b-3(c) regulatory

"transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)"

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donnelly Brian J

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commerical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		5,000(1)	A	$3.936	573,363	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were acquired under the Issuer's Amended and Restated 2012 Employee Stock Purchase Plan, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

	By: Justin Hunter For: Brian J. Donnelly	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MYRIAD GENETICS INC (MYGN) report for Brian J. Donnelly?

MYRIAD GENETICS reported that Chief Commercial Officer Brian J. Donnelly acquired 5,000 shares of common stock. The shares were obtained through the company’s Amended and Restated 2012 Employee Stock Purchase Plan in an exempt, compensation-related transaction rather than an open-market purchase.

How many MYGN shares did Brian J. Donnelly acquire and at what price?

Brian J. Donnelly acquired 5,000 shares of MYRIAD GENETICS common stock at $3.936 per share. These shares were obtained through the company’s employee stock purchase plan, reflecting a routine equity acquisition linked to his role rather than a discretionary market trade.

How many MYGN shares does Brian J. Donnelly own after this Form 4 transaction?

Following the reported acquisition, Brian J. Donnelly directly owns 573,363 shares of MYRIAD GENETICS common stock. The 5,000 additional shares represent a small increase in his overall holdings and were acquired under the company’s Amended and Restated 2012 Employee Stock Purchase Plan.

Was Brian J. Donnelly’s MYGN share acquisition an open-market purchase?

No, the 5,000 MYGN shares were acquired under the company’s Amended and Restated 2012 Employee Stock Purchase Plan. The footnote states the transactions were exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating a plan-based, compensation-related acquisition rather than an open-market trade.

What plan was used for Brian J. Donnelly’s 5,000-share MYGN acquisition?

The acquisition was made under MYRIAD GENETICS’ Amended and Restated 2012 Employee Stock Purchase Plan. According to the footnote, transactions under this plan are exempt under Rule 16b-3(d) and Rule 16b-3(c), characterizing the event as a routine, plan-based share purchase for an employee.

What is the significance of Rule 16b-3 exemptions in Brian J. Donnelly’s MYGN transaction?

The filing notes the transaction is exempt under Rule 16b-3(d) and Rule 16b-3(c), which cover certain insider transactions under compensatory plans. This indicates Donnelly’s 5,000-share acquisition was made through an approved employee plan, not as a discretionary open-market trading decision.